The evaluation of larger series of leukemia samples (myeloproliferative diseases, CML, and ALL) for PTPRG expression by flow cytometry, in addition to in situ techniques, as well as the detailed definition of its signaling pathway, may reveal additional details regarding CML biology. Here, PTPRG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.